This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation sought 13 different vaccine types including hepatitis, pneumococcal, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal, HPV, varicella, and pneumococcal conjugate, with minimum and maximum order quantities specified. Glaxosmithkline has also received other federal IDV awards from agencies like the VA and DLA to supply seasonal influenza vaccines, vaccine storage services, and the antiviral medication zanamivir, demonstrating the company's extensive experience providing pharmaceutical products and services to the U.S. government.
Generated 12/17/24, 9:06 AM